Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


13.02.2017

3 Ann Oncol
1 Ann Surg Oncol
8 Anticancer Res
1 BMC Cancer
1 BMJ
1 Cancer Chemother Pharmacol
1 Carcinogenesis
1 J Cancer Res Clin Oncol
1 J Thorac Cardiovasc Surg
1 J Thorac Oncol
1 Lancet Respir Med
2 PLoS Med
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. REMON J, Soria JC
    Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency.
    Ann Oncol. 2016 Oct 25. doi: 10.1093.
    PubMed     Text format    

  2. PAZ-ARES L, Tan EH, O'Byrne K, Zhang L, et al
    Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
    Ann Oncol. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    

  3. HUI R, Garon EB, Goldman JW, Leighl NB, et al
    Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
    Ann Oncol. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


    Ann Surg Oncol

  4. YOUNG KA, Efiong E, Dove JT, Blansfield JA, et al
    External Validation of a Survival Nomogram for Non-Small Cell Lung Cancer Using the National Cancer Database.
    Ann Surg Oncol. 2017 Feb 6. doi: 10.1245/s10434-017-5795.
    PubMed     Text format     Abstract available


    Anticancer Res

  5. SIRIMANGKALAKITTI N, Chamni S, Suwanborirux K, Chanvorachote P, et al
    Renieramycin M Attenuates Cancer Stem Cell-like Phenotypes in H460 Lung Cancer Cells.
    Anticancer Res. 2017;37:615-621.
    PubMed     Text format     Abstract available

  6. ISHIKURA N, Yanagisawa M, Noguchi-Sasaki M, Iwai T, et al
    Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models.
    Anticancer Res. 2017;37:623-629.
    PubMed     Text format     Abstract available

  7. SHOJI F, Haratake N, Akamine T, Takamori S, et al
    The Preoperative Controlling Nutritional Status Score Predicts Survival After Curative Surgery in Patients with Pathological Stage I Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:741-747.
    PubMed     Text format     Abstract available

  8. TAKEDA K, Yamasaki A, Igishi T, Kawasaki Y, et al
    Frequency of Epidermal Growth Factor Receptor Mutation in Smokers with Lung Cancer Without Pulmonary Emphysema.
    Anticancer Res. 2017;37:765-771.
    PubMed     Text format     Abstract available

  9. TOYOKAWA G, Kozuma Y, Matsubara T, Haratake N, et al
    Radiological Features of the Surgically Resected Small-sized Small-cell Lung Cancer on Computed Tomography.
    Anticancer Res. 2017;37:877-881.
    PubMed     Text format     Abstract available

  10. YAMASAKI M, Murakami I, Nakano K, Doi M, et al
    Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:923-928.
    PubMed     Text format     Abstract available

  11. SONE K, Oguri T, Nakao M, Kagawa Y, et al
    CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
    Anticancer Res. 2017;37:935-939.
    PubMed     Text format     Abstract available

  12. RAFEI H, El-Bahesh E, Finianos A, Nassereddine S, et al
    Immune-based Therapies for Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:377-387.
    PubMed     Text format     Abstract available


    BMC Cancer

  13. LIN C, Majoor CJ, Roelofs JJ, de Kruif MD, et al
    Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer.
    BMC Cancer. 2017;17:113.
    PubMed     Text format     Abstract available


    BMJ

  14. RAMPINELLI C, De Marco P, Origgi D, Maisonneuve P, et al
    Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis.
    BMJ. 2017;356:j347.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  15. IMAI H, Kuwako T, Kaira K, Masuda T, et al
    Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Feb 6. doi: 10.1007/s00280-016-3232.
    PubMed     Text format     Abstract available


    Carcinogenesis

  16. YUAN JM, Nelson HH, Carmella SG, Wang R, et al
    CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study.
    Carcinogenesis. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    


    J Cancer Res Clin Oncol

  17. KLUPCZYNSKA A, Derezinski P, Garrett TJ, Rubio VY, et al
    Study of early stage non-small-cell lung cancer using Orbitrap-based global serum metabolomics.
    J Cancer Res Clin Oncol. 2017 Feb 6. doi: 10.1007/s00432-017-2347.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  18. BURT BM
    Thoracoscopic lobectomy for clinical N2 and N1 lung cancer: Innovation outpacing standard of care.
    J Thorac Cardiovasc Surg. 2017 Jan 10. pii: S0022-5223(17)30004.
    PubMed     Text format    


    J Thorac Oncol

  19. CHUANG JC, Stehr H, Liang Y, Das M, et al
    ERBB2-mutated metastatic non-small cell lung cancer: response and resistance to targeted therapies.
    J Thorac Oncol. 2017 Feb 3. pii: S1556-0864(17)30090.
    PubMed     Text format     Abstract available


    Lancet Respir Med

  20. BAGCCHI S
    Lung cancer survival only increases by a small amount despite recent treatment advances.
    Lancet Respir Med. 2017 Feb 3. pii: S2213-2600(17)30041.
    PubMed     Text format    


    PLoS Med

  21. TEN HAAF K, Tammemagi MC, Bondy SJ, van der Aalst CM, et al
    Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
    PLoS Med. 2017;14:e1002225.
    PubMed     Text format     Abstract available

  22. SHAPIRO SD
    Refining Lung Cancer Screening Criteria in the Era of Value-Based Medicine.
    PLoS Med. 2017;14:e1002226.
    PubMed     Text format     Abstract available


    PLoS One

  23. WALKER R, Deppen S, Smith G, Shi C, et al
    68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer.
    PLoS One. 2017;12:e0171301.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: